Solara Active Pharma Sciences has completed the sale of 100% stake in SeQuent Penems to Symbio Generrics India for a cash consideration of Rs.12.50 crore on 25 April 2024. Hence, SeQuent Penems ceased to be a subsidiary of the Company.Powered by Capital Market - Live News

The Board of Solara Active Pharma Sciences at its meeting held on 25 March 2024 has approved the sale of 100% shareholding in SeQuent Penems, a wholly owned subsidiary of the company. Powered by Capital Market - Live News

Net loss of Solara Active Pharma Sciences reported to Rs 275.34 crore in the quarter ended December 2023 as against net profit of Rs 0.45 crore during the previous quarter ended December 2022. Sales declined 36.99% to Rs 248.73 crore in the quarter ended December 2023 as against Rs 394.75 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales248.73394.75 -37 OPM %-65.0111.40 - PBDT-186.6128.53 PL PBT-212.570.55 PL NP-275.340.45 PL Powered by Capital Market - Live News

Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 14 February 2024.Powered by Capital Market - Live News

Net Loss of Solara Active Pharma Sciences reported to Rs 17.16 crore in the quarter ended September 2023 as against net loss of Rs 9.96 crore during the previous quarter ended September 2022. Sales rose 25.67% to Rs 425.24 crore in the quarter ended September 2023 as against Rs 338.37 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales425.24338.37 26 OPM %8.858.15 - PBDT14.379.33 54 PBT-11.84-19.30 39 NP-17.16-9.96 -72 Powered by Capital Market - Live News